Transcriptional Analysis Reveals Distinct Subtypes in Amyotrophic Lateral Sclerosis: Implications for Personalized Therapy

References

• Pasinelli P , BrownRH. Molecular biology of amyotrophic lateral sclerosis: insights from genetics. Nat. Rev. Neurosci.7 (9), 710–723 (2006).
   PubMed Web of Science ®Google Scholar
• Turner MR , PartonMJ, LeighPN. Clinical trials in ALS: an overview. Semin. Neurol.21 (2), 167–175 (2001).
   PubMed Web of Science ®Google Scholar
• Lederer CW , TorrisiA, PantelidouM, SantamaN, CavallaroS. Pathways and genes differentially expressed in the motor cortex of patients with sporadic amyotrophic lateral sclerosis. BMC Genomics8 (1), 26 (2007).
   PubMedGoogle Scholar
• Ferraiuolo L , KirbyJ, GriersonAJ, SendtnerM, ShawPJ. Molecular pathways of motor neuron injury in amyotrophic lateral sclerosis. Nat. Rev. Neurol.7 (11), 616–630 (2011).
   PubMed Web of Science ®Google Scholar
• Gasparini G , LongoR. The paradigm of personalized therapy in oncology. Expert Opin. Ther. Targets16 (Suppl. 1), S7–S16 (2012).
   PubMedGoogle Scholar
• Sharp FR , XuH, LitLet al. The future of genomic profiling of neurological diseases using blood. Arch. Neurol.63 (11), 1529–1536 (2006).
   PubMedGoogle Scholar
• Aronica E , BaasF, IyerA, Ten AsbroekAL, MorelloG, CavallaroS. Molecular classification of amyotrophic lateral sclerosis by unsupervised clustering of gene expression in motor cortex. Neurobiol. Dis.74C, 359–376 (2014).
   Google Scholar
• Glantz LA , GilmoreJH, LiebermanJA, JarskogLF. Apoptotic mechanisms and the synaptic pathology of schizophrenia. Schizophr. Res.81 (1), 47–63 (2006).
   PubMed Web of Science ®Google Scholar
• Cudkowicz ME , AndresPL, MacdonaldSAet al. Phase 2 study of sodium phenylbutyrate in ALS. Amyotroph. Lateral. Scler.10 (2), 99–106 (2009).
   PubMed Web of Science ®Google Scholar
• Ryu H , SmithK, CameloSIet al. Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice. J. Neurochem.93 (5), 1087–1098 (2005).
   PubMed Web of Science ®Google Scholar
• Raoul C , BuhlerE, SadeghiCet al. Chronic activation in presymptomatic amyotrophic lateral sclerosis (ALS) mice of a feedback loop involving Fas, Daxx, and FasL. Proc. Natl Acad. Sci. USA103 (15), 6007–6012 (2006).
   PubMed Web of Science ®Google Scholar
• Neymotin A , PetriS, CalingasanNYet al. Lenalidomide (revlimid) administration at symptom onset is neuroprotective in a mouse model of amyotrophic lateral sclerosis. Exp. Neurol.220 (1), 191–197 (2009).
   PubMed Web of Science ®Google Scholar
• Camandola S , MattsonMP. Nf-kappa b as a therapeutic target in neurodegenerative diseases. Expert Opin. Ther. Targets11 (2), 123–132 (2007).
   PubMed Web of Science ®Google Scholar
• Feng XH , YuanW, PengY, LiuMS, CuiLY. Therapeutic effects of dl-3-n-butylphthalide in a transgenic mouse model of amyotrophic lateral sclerosis. Chin. Med. J. (Engl.)125 (10), 1760–1766 (2012).
   PubMed Web of Science ®Google Scholar
• Vincent I , PaeCI, HallowsJL. The cell cycle and human neurodegenerative disease. Prog. Cell Cycle Res.5, 31–41 (2003).
   PubMedGoogle Scholar
• Wang W , BuB, XieM, ZhangM, YuZ, TaoD. Neural cell cycle dysregulation and central nervous system diseases. Prog. Neurobiol.89 (1), 1–17 (2009).
   PubMed Web of Science ®Google Scholar
• Nguyen MD , BoudreauM, KrizJ, Couillard-DespresS, KaplanDR, JulienJP. Cell cycle regulators in the neuronal death pathway of amyotrophic lateral sclerosis caused by mutant superoxide dismutase 1. J. Neurosci.23 (6), 2131–2140 (2003).
   PubMed Web of Science ®Google Scholar
• Liu DZ , AnderBP. Cell cycle inhibition without disruption of neurogenesis is a strategy for treatment of aberrant cell cycle diseases: an update. TheScientificWorldJournal2012, 491737 (2012).
   PubMedGoogle Scholar
• Zhang Y , QuD, MorrisEJet al. The Chk1/Cdc25A pathway as activators of the cell cycle in neuronal death induced by camptothecin. J. Neurosci.26 (34), 8819–8828 (2006).
   PubMed Web of Science ®Google Scholar
• Becker EB , BonniA. Cell cycle regulation of neuronal apoptosis in development and disease. Prog. Neurobiol.72 (1), 1–25 (2004).
   PubMed Web of Science ®Google Scholar
• Tota S , KamatPK, ShuklaR, NathC. Improvement of brain energy metabolism and cholinergic functions contributes to the beneficial effects of silibinin against streptozotocin induced memory impairment. Behav. Brain Res.221 (1), 207–215 (2011).
   PubMed Web of Science ®Google Scholar
• Boutahar N , WierinckxA, CamdessancheJPet al. Differential effect of oxidative or excitotoxic stress on the transcriptional profile of amyotrophic lateral sclerosis-linked mutant sod1 cultured neurons. J. Neurosci. Res.89 (9), 1439–1450 (2011).
   PubMed Web of Science ®Google Scholar
• Niebroj-Dobosz I , JanikP, SokolowskaB, KwiecinskiH. Matrix metalloproteinases and their tissue inhibitors in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Eur. J. Neurol.17 (2), 226–231 (2010).
   PubMed Web of Science ®Google Scholar
• Jarvelainen H , SainioA, KouluM, WightTN, PenttinenR. Extracellular matrix molecules: potential targets in pharmacotherapy. Pharmacol. Rev.61 (2), 198–223 (2009).
   PubMed Web of Science ®Google Scholar
• Kiaei M , PetriS, KipianiKet al. Thalidomide and lenalidomide extend survival in a transgenic mouse model of amyotrophic lateral sclerosis. J. Neurosci.26 (9), 2467–2473 (2006).
   PubMed Web of Science ®Google Scholar
• Stommel EW , CohenJA, FadulCEet al. Efficacy of thalidomide for the treatment of amyotrophic lateral sclerosis: a phase II open label clinical trial. Amyotroph. Lateral Scler.10 (5–6), 393–404 (2009).
   PubMed Web of Science ®Google Scholar
• Costa R , SperettaE, CrowtherDC, CardosoI. Testing the therapeutic potential of doxycycline in a drosophila melanogaster model of Alzheimer disease. J. Biol. Chem.286 (48), 41647–41655 (2011).
   PubMed Web of Science ®Google Scholar
• Dong W , VuleticS, AlbersJJ. Differential effects of simvastatin and pravastatin on expression of Alzheimer's disease-related genes in human astrocytes and neuronal cells. J. Lipid Res.50 (10), 2095–2102 (2009).
   PubMed Web of Science ®Google Scholar
• Grace EA , BusciglioJ. Aberrant activation of focal adhesion proteins mediates fibrillar amyloid beta-induced neuronal dystrophy. J. Neurosci.23 (2), 493–502 (2003).
   PubMed Web of Science ®Google Scholar
• Weyant MJ , CarothersAM, BertagnolliME, BertagnolliMM. Colon cancer chemopreventive drugs modulate integrin-mediated signaling pathways. Clin. Cancer Res.6 (3), 949–956 (2000).
   PubMed Web of Science ®Google Scholar
• Kiaei M , KipianiK, PetriSet al. Integrative role of cPLA with COX-2 and the effect of non-steriodal anti-inflammatory drugs in a transgenic mouse model of amyotrophic lateral sclerosis. J. Neurochem.93 (2), 403–411 (2005).
   PubMed Web of Science ®Google Scholar
• De Vos KJ , GriersonAJ, AckerleyS, MillerCC. Role of axonal transport in neurodegenerative diseases. Annu. Rev. Neurosci.31, 151–173 (2008).
   PubMed Web of Science ®Google Scholar
• De Winter F , VoT, StamFJet al. The expression of the chemorepellent semaphorin 3a is selectively induced in terminal Schwann cells of a subset of neuromuscular synapses that display limited anatomical plasticity and enhanced vulnerability in motor neuron disease. Mol. Cell. Neurosci.32 (1–2), 102–117 (2006).
   PubMed Web of Science ®Google Scholar
• Axelrod A , EliasenAM, ChinMR, ZlotkowskiK, SiegelD. Syntheses of xanthofulvin and vinaxanthone, natural products enabling spinal cord regeneration. Angew. Chem. Int. Ed. Engl.52 (12), 3421–3424 (2013).
   PubMed Web of Science ®Google Scholar
• Bajaj NP . Cyclin-dependent kinase-5 (CDK5) and amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Other Motor Neuron Disord.1 (5), 319–327 (2000).
   PubMed Web of Science ®Google Scholar
• Appert-Collin A , HugelB, LevyRet al. Cyclin dependent kinase inhibitors prevent apoptosis of postmitotic mouse motoneurons. Life Sci.79 (5), 484–490 (2006).
   PubMed Web of Science ®Google Scholar
• Mapelli M , MassimilianoL, CrovaceCet al. Mechanism of cdk5/p25 binding by cdk inhibitors. J. Med. Chem.48 (3), 671–679 (2005).
   PubMed Web of Science ®Google Scholar
• Shemesh OA , SpiraME. Rescue of neurons from undergoing hallmark tau-induced Alzheimer's disease cell pathologies by the antimitotic drug paclitaxel. Neurobiol. Dis.43 (1), 163–175 (2011).
   PubMed Web of Science ®Google Scholar
• Sunyach C , MichaudM, ArnouxTet al. Olesoxime delays muscle denervation, astrogliosis, microglial activation and motoneuron death in an ALS mouse model. Neuropharmacology62 (7), 2346–2352 (2012).
   PubMed Web of Science ®Google Scholar
• Mccombe PA , HendersonRD. The role of immune and inflammatory mechanisms in ALS. Curr. Mol. Med.11 (3), 246–254 (2011).
   PubMed Web of Science ®Google Scholar
• Calvo A , MogliaC, BalmaM, ChioA. Involvement of immune response in the pathogenesis of amyotrophic lateral sclerosis: a therapeutic opportunity?CNS Neurol. Disord. Drug Targets9 (3), 325–330 (2010).
   PubMed Web of Science ®Google Scholar
• Casula M , IyerAM, SplietWGet al. Toll-like receptor signaling in amyotrophic lateral sclerosis spinal cord tissue. Neuroscience179, 233–243 (2011).
   PubMed Web of Science ®Google Scholar
• Villa P , TriulziS, CavalieriBet al. The interleukin-8 (IL-8/CXCL8) receptor inhibitor reparixin improves neurological deficits and reduces long-term inflammation in permanent and transient cerebral ischemia in rats. Mol. Med.13 (3–4), 125–133 (2007).
   PubMed Web of Science ®Google Scholar
• Suzuki Y , HattoriK, HamanakaJet al. Pharmacological inhibition of TLR4-NOX4 signal protects against neuronal death in transient focal ischemia. Sci. Rep.2, 896 (2012).
   PubMed Web of Science ®Google Scholar
• Akashi S , SaitohS, WakabayashiYet al. Lipopolysaccharide interaction with cell surface Toll-like receptor 4-MD-2: higher affinity than that with MD-2 or CD14. J. Exp. Med.198 (7), 1035–1042 (2003).
   PubMed Web of Science ®Google Scholar
• De Paola M , BuanneP, BiordiL, BertiniR, GhezziP, MenniniT. Chemokine MIP-2/CXCL2, acting on CXCR2, induces motor neuron death in primary cultures. Neuroimmunomodulation14 (6), 310–316 (2007).
   PubMed Web of Science ®Google Scholar
• Lampson LA , KushnerPD, SobelRA. Major histocompatibility complex antigen expression in the affected tissues in amyotrophic lateral sclerosis. Ann. Neurol.28 (3), 365–372 (1990).
   PubMed Web of Science ®Google Scholar
• Scorisa JM , FreriaCM, VictorioSC, BarbizanR, ZanonRG, OliveiraAL. Glatiramer acetate treatment increases stability of spinal synapses and down regulates MHC I during the course of eae. Int. J. Biol. Sci.7 (8), 1188–1202 (2011).
   PubMed Web of Science ®Google Scholar
• Xin J , WainwrightDA, MesnardNA, SerpeCJ, SandersVM, JonesKJ. Il-10 within the CNS is necessary for CD4+ t cells to mediate neuroprotection. Brain. Behav. Immun.25 (5), 820–829 (2011).
   PubMed Web of Science ®Google Scholar
• Arnon R , AharoniR. Mechanism of action of glatiramer acetate in multiple sclerosis and its potential for the development of new applications. Proc. Natl Acad. Sci. USA101 (Suppl. 2), 14593–14598 (2004).
   PubMed Web of Science ®Google Scholar
• Moreau C , DevosD, Brunaud-DanelVet al. Elevated IL-6 and TNF-alpha levels in patients with ALS: inflammation or hypoxia? Neurology 65 (12), 1958–1960 (2005).
   PubMed Web of Science ®Google Scholar
• Shi N , KawanoY, TateishiTet al. Increased IL-13-producing t cells in ALS: positive correlations with disease severity and progression rate. J. Neuroimmunol.182 (1–2), 232–235 (2007).
   PubMed Web of Science ®Google Scholar
• Rentzos M , RombosA, NikolaouCet al. Interleukin-17 and interleukin-23 are elevated in serum and cerebrospinal fluid of patients with ALS: a reflection of th17 cells activation? Acta Neurol. Scand. 122 (6), 425–429 (2010).
   PubMed Web of Science ®Google Scholar
• Mizwicki MT , FialaM, MagpantayLet al. Tocilizumab attenuates inflammation in ALS patients through inhibition of IL6 receptor signaling. Am. J. Neurodegener. Dis.1 (3), 305–315 (2012).
   PubMedGoogle Scholar
• Vom Berg J , ProkopS, MillerKRet al. Inhibition of IL-12/IL-23 signaling reduces Alzheimer's disease-like pathology and cognitive decline. Nat. Med.18 (12), 1812–1819 (2012).
   PubMed Web of Science ®Google Scholar
• Nicolas CS , AmiciM, BortolottoZAet al. The role of JAK-STAT signaling within the CNS. JAKSTAT2 (1), e22925 (2013).
   PubMedGoogle Scholar
• Ignarro RS , VieiraAS, SartoriCR, LangoneF, RogerioF, ParadaCA. JAK2 inhibition is neuroprotective and reduces astrogliosis after quinolinic acid striatal lesion in adult mice. J. Chem. Neuroanat.48–49, 14–22 (2013).
   PubMed Web of Science ®Google Scholar
• Trieu VN , LiuR, LiuXP, UckunFM. A specific inhibitor of janus kinase-3 increases survival in a transgenic mouse model of amyotrophic lateral sclerosis. Biochem. Biophys. Res. Commun.267 (1), 22–25 (2000).
   PubMed Web of Science ®Google Scholar
• Chao MV , RajagopalR, LeeFS. Neurotrophin signalling in health and disease. Clin. Sci. (London)110 (2), 167–173 (2006).
   PubMed Web of Science ®Google Scholar
• Henriques A , PitzerC, SchneiderA. Neurotrophic growth factors for the treatment of amyotrophic lateral sclerosis: where do we stand?Front. Neurosci.4, 32 (2010).
   PubMed Web of Science ®Google Scholar
• Liu B , ChenH, JohnsTG, NeufeldAH. Epidermal growth factor receptor activation: an upstream signal for transition of quiescent astrocytes into reactive astrocytes after neural injury. J. Neurosci.26 (28), 7532–7540 (2006).
   PubMed Web of Science ®Google Scholar
• Mizuno M , SotoyamaH, NambaHet al. Erbb inhibitors ameliorate behavioral impairments of an animal model for schizophrenia: implication of their dopamine-modulatory actions. Transl. Psychiat.3, e252 (2013).
   PubMed Web of Science ®Google Scholar
• Boston-Howes W , WilliamsEO, BogushA, ScolereM, PasinelliP, TrottiD. Nordihydroguaiaretic acid increases glutamate uptake in vitro and in vivo: therapeutic implications for amyotrophic lateral sclerosis. Exp. Neurol.213 (1), 229–237 (2008).
   PubMed Web of Science ®Google Scholar
• Trieu VN , UckunFM. Genistein is neuroprotective in murine models of familial amyotrophic lateral sclerosis and stroke. Biochem. Biophys. Res. Commun.258 (3), 685–688 (1999).
   PubMed Web of Science ®Google Scholar
• Chan CF , Lin-ShiauSY. Suramin prevents cerebellar granule cell-death induced by dequalinium. Neurochem. Int.38 (2), 135–143 (2001).
   PubMed Web of Science ®Google Scholar
• Heneberg P . Use of protein tyrosine phosphatase inhibitors as promising targeted therapeutic drugs. Curr. Med. Chem.16 (6), 706–733 (2009).
   PubMed Web of Science ®Google Scholar
• Xu K , DaiXL, HuangHC, JiangZF. Targeting HDACs: a promising therapy for Alzheimer's disease. Oxid. Med. Cell. Longev.2011, 143269 (2011).
   PubMed Web of Science ®Google Scholar
• Goureau O , LepoivreM, BecquetF, CourtoisY. Differential regulation of inducible nitric oxide synthase by fibroblast growth factors and transforming growth factor beta in bovine retinal pigmented epithelial cells: inverse correlation with cellular proliferation. Proc. Natl Acad. Sci. USA90 (9), 4276–4280 (1993).
   PubMed Web of Science ®Google Scholar
• Janssen C , SchmalbachS, BoeseltS, SarletteA, DenglerR, PetriS. Differential histone deacetylase mRNA expression patterns in amyotrophic lateral sclerosis. J. Neuropathol. Exp. Neurol.69 (6), 573–581 (2010).
   PubMed Web of Science ®Google Scholar
• Carlesi C , PasqualiL, PiazzaSet al. Strategies for clinical approach to neurodegeneration in amyotrophic lateral sclerosis. Arch. Ital. Biol.149 (1), 151–167 (2011).
   PubMed Web of Science ®Google Scholar
• Manaker S , CaineSB, WinokurA. Alterations in receptors for thyrotropin-releasing hormone, serotonin, and acetylcholine in amyotrophic lateral sclerosis. Neurology38 (9), 1464–1474 (1988).
   PubMed Web of Science ®Google Scholar
• Lu JM , NurkoJ, WeakleySMet al. Molecular mechanisms and clinical applications of nordihydroguaiaretic acid (NDGA) and its derivatives: an update. Med. Sci. Monit.16 (5), RA93–100K (2010).
   PubMed Web of Science ®Google Scholar
• Khomane KS , MeenaCL, JainR, BansalAK. Novel thyrotropin-releasing hormone analogs: a patent review. Expert Opin. Ther. Pat.21 (11), 1673–1691 (2011).
   PubMed Web of Science ®Google Scholar
• Chung YH , JooKM, ShinCMet al. Brain Res. 994 (2), 253–259 (2003).
   PubMed Web of Science ®Google Scholar
• Renna M , BentoCF, FlemingAet al. IGF-1 receptor antagonism inhibits autophagy. Hum. Mol. Genet.22 (22), 4528–4544 (2013).
   PubMed Web of Science ®Google Scholar
• Yan J , XuY, ZhuCet al. Simvastatin prevents dopaminergic neurodegeneration in experimental parkinsonian models: the association with anti-inflammatory responses. PLoS ONE6 (6), e20945 (2011).
   PubMed Web of Science ®Google Scholar
• Ramirez C , TerceroI, PinedaA, BurgosJS. Simvastatin is the statin that most efficiently protects against kainate-induced excitotoxicity and memory impairment. J. Alzheimers Dis.24 (1), 161–174 (2011).
   PubMed Web of Science ®Google Scholar
• Cassina P , PeharM, VargasMRet al. Astrocyte activation by fibroblast growth factor-1 and motor neuron apoptosis: Implications for amyotrophic lateral sclerosis. J. Neurochem.93 (1), 38–46 (2005).
   PubMed Web of Science ®Google Scholar
• Mojsilovic-Petrovic J , JeongGB, CrockerAet al. Protecting motor neurons from toxic insult by antagonism of adenosine A2a and Trk receptors. J. Neurosci.26 (36), 9250–9263 (2006).
   PubMed Web of Science ®Google Scholar
• Cazorla M , PremontJ, MannA, GirardN, KellendonkC, RognanD. Identification of a low-molecular weight TrkB antagonist with anxiolytic and antidepressant activity in mice. J. Clin. Invest.121 (5), 1846–1857 (2011).
   PubMed Web of Science ®Google Scholar
• Cazorla M , JouvenceauA, RoseCet al. Cyclotraxin-B, the first highly potent and selective TrkB inhibitor, has anxiolytic properties in mice. PLoS ONE5 (3), e9777 (2010).
   PubMed Web of Science ®Google Scholar
• Brockington A , WhartonSB, FernandoMet al. Expression of vascular endothelial growth factor and its receptors in the central nervous system in amyotrophic lateral sclerosis. J. Neuropathol. Exp. Neurol.65 (1), 26–36 (2006).
   PubMed Web of Science ®Google Scholar
• Tovar-Y-Romo LB , TapiaR. Delayed administration of VEGF rescues spinal motor neurons from death with a short effective time frame in excitotoxic experimental models in vivo. ASN Neuro4 (2), e00081 (2012).
   PubMed Web of Science ®Google Scholar
• Zheng C , NennesmoI, FadeelB, HenterJI. Vascular endothelial growth factor prolongs survival in a transgenic mouse model of ALS. Ann. Neurol.56 (4), 564–567 (2004).
   PubMed Web of Science ®Google Scholar
• Nefussy B , DroryVE. Moving toward a predictive and personalized clinical approach in amyotrophic lateral sclerosis: novel developments and future directions in diagnosis, genetics, pathogenesis and therapies. EPMA J.1 (2), 329–341 (2010).
   PubMedGoogle Scholar
• Gordon PH , CheungYK, LevinBet al. A novel, efficient, randomized selection trial comparing combinations of drug therapy for ALS. Amyotroph. Lateral. Scler.9 (4), 212–222 (2008).
   PubMed Web of Science ®Google Scholar
• Foerster BR , CallaghanBC, PetrouM, EddenRA, ChenevertTL, FeldmanEL. Decreased motor cortex gamma-aminobutyric acid in amyotrophic lateral sclerosis. Neurology78 (20), 1596–1600 (2012).
   PubMed Web of Science ®Google Scholar
• Adeosun SO , HouX, JiaoYet al. Allopregnanolone reinstates tyrosine hydroxylase immunoreactive neurons and motor performance in an MPTP-lesioned mouse model of parkinson's disease. PLoS ONE7 (11), e50040 (2012).
   PubMed Web of Science ®Google Scholar
• Kumar A , GoyalR. Possible gabaergic modulation in the protective effect of zolpidem in acute hypoxic stress-induced behavior alterations and oxidative damage. Neurochem. Res.33 (3), 370–377 (2008).
   PubMed Web of Science ®Google Scholar
• Fung SJ , XiMC, ZhangJHet al. Eszopiclone prevents excitotoxicity and neurodegeneration in the hippocampus induced by experimental apnea. Sleep32 (12), 1593–1601 (2009).
   PubMed Web of Science ®Google Scholar
• Ishimaru H , TakahashiA, IkarashiY, MaruyamaY. Effects of MK-801 and pentobarbital on cholinergic terminal damage and delayed neuronal death in the ischemic gerbil hippocampus. Brain Res. Bull.43 (1), 81–85 (1997).
   PubMed Web of Science ®Google Scholar
• Shaw PJ , IncePG. Glutamate, excitotoxicity and amyotrophic lateral sclerosis. J. Neurol.244 (Suppl. 2), S3–S14 (1997).
   PubMedGoogle Scholar
• Armstrong GA , DrapeauP. Calcium channel agonists protect against neuromuscular dysfunction in a genetic model of TDP-43 mutation in ALS. J. Neurosci.33 (4), 1741–1752 (2013).
   PubMed Web of Science ®Google Scholar
• Tortarolo M , GrignaschiG, CalvaresiNet al. Glutamate ampa receptors change in motor neurons of SOD1G93Atransgenic mice and their inhibition by a noncompetitive antagonist ameliorates the progression of amytrophic lateral sclerosis-like disease. J. Neurosci. Res.83 (1), 134–146 (2006).
   PubMed Web of Science ®Google Scholar
• Van Damme P , LeyssenM, CallewaertG, RobberechtW, Van Den BoschL. The AMPA receptor antagonist NBQX prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis. Neurosci. Lett.343 (2), 81–84 (2003).
   PubMed Web of Science ®Google Scholar
• Albo F , PieriM, ZonaC. Modulation of AMPAreceptors in spinal motor neurons by the neuroprotective agent riluzole. J. Neurosci. Res.78 (2), 200–207 (2004).
   PubMed Web of Science ®Google Scholar
• Paizs M , TortaroloM, BendottiC, EngelhardtJI, SiklosL. Talampanel reduces the level of motoneuronal calcium in transgenic mutant SOD1 mice only if applied presymptomatically. Amyotroph. Lateral. Scler.12 (5), 340–344 (2011).
   PubMed Web of Science ®Google Scholar
• Pascuzzi RM , ShefnerJ, ChappellASet al. A Phase II trial of talampanel in subjects with amyotrophic lateral sclerosis. Amyotroph. Lateral. Scler.11 (3), 266–271 (2010).
   PubMed Web of Science ®Google Scholar
• Whitehouse PJ , WamsleyJK, ZarbinMA, PriceDL, TourtellotteWW, KuharMJ. Amyotrophic lateral sclerosis: alterations in neurotransmitter receptors. Ann. Neurol.14 (1), 8–16 (1983).
   PubMed Web of Science ®Google Scholar
• Van Kampen JM , EckmanCB. Agonist-induced restoration of hippocampal neurogenesis and cognitive improvement in a model of cholinergic denervation. Neuropharmacology58 (6), 921–929 (2010).
   PubMed Web of Science ®Google Scholar
• Turner BJ , RembachA, SparkR, LopesEC, CheemaSS. Opposing effects of low and high-dose clozapine on survival of transgenic amyotrophic lateral sclerosis mice. J. Neurosci. Res.74 (4), 605–613 (2003).
   PubMed Web of Science ®Google Scholar
• Kawajiri M , MogiM, HigakiNet al. Reduced angiotensin II levels in the cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Acta Neurol. Scand.119 (5), 341–344 (2009).
   PubMed Web of Science ®Google Scholar
• Iwasaki Y , IchikawaY, IgarashiO, KinoshitaM, IkedaK. Trophic effect of olmesartan, a novel AT1R antagonist, on spinal motor neurons in vitro and in vivo. Neurol. Res.24 (5), 468–472 (2002).
   PubMed Web of Science ®Google Scholar
• Saavedra JM . Angiotensin II AT(1) receptor blockers as treatments for inflammatory brain disorders. Clin. Sci. (London)123 (10), 567–590 (2012).
   PubMed Web of Science ®Google Scholar
• Dominguez-Meijide A , Villar-ChedaB, Garrido-GilP, Sierrra-ParedesG, GuerraMJ, Labandeira-GarciaJL. Effect of chronic treatment with angiotensin type 1 receptor antagonists on striatal dopamine levels in normal rats and in a rat model of parkinson's disease treated with L-DOPA. Neuropharmacology76 (Pt A), 156–168 (2014).
   PubMedGoogle Scholar
• Tsukuda K , MogiM, IwanamiJet al. Cognitive deficit in amyloid-beta-injected mice was improved by pretreatment with a low dose of telmisartan partly because of peroxisome proliferator-activated receptor-gamma activation. Hypertension54 (4), 782–787 (2009).
   PubMed Web of Science ®Google Scholar
• Wu X , KiharaT, HongoH, AkaikeA, NiidomeT, SugimotoH. Angiotensin receptor type 1 antagonists protect against neuronal injury induced by oxygen-glucose depletion. Br. J. Pharmacol.161 (1), 33–50 (2010).
   PubMed Web of Science ®Google Scholar
• Rothstein JD . Current hypotheses for the underlying biology of amyotrophic lateral sclerosis. Ann. Neurol.65 (Suppl. 1), S3–S9 (2009).
   PubMed Web of Science ®Google Scholar
• Tonari M , KurimotoT, HorieT, SugiyamaT, IkedaT, OkuH. Blocking endothelin-b receptors rescues retinal ganglion cells from optic nerve injury through suppression of neuroinflammation. Invest. Ophthalmol. Vis. Sci.53 (7), 3490–3500 (2012).
   PubMed Web of Science ®Google Scholar
• Filipovich T , Fleisher-BerkovichS. Regulation of glial inflammatory mediators synthesis: possible role of endothelins. Peptides29 (12), 2250–2256 (2008).
   PubMed Web of Science ®Google Scholar
• Koyama Y , KotaniM, SawamuraT, KuribayashiM, KonishiR, MichinagaS. Different actions of endothelin-1 on chemokine production in rat cultured astrocytes: reduction of CX3CL1/fractalkine and an increase in CCL2/MCP-1 and CXCL1/CINC-1. J. Neuroinflamm.10, 51 (2013).
   PubMed Web of Science ®Google Scholar
• Cozzolino M , CarriMT. Mitochondrial dysfunction in ALS. Prog. Neurobiol.97 (2), 54–66 (2012).
   PubMed Web of Science ®Google Scholar
• Kira Y , NishikawaM, OchiA, SatoE, InoueM. L-carnitine suppresses the onset of neuromuscular degeneration and increases the life span of mice with familial amyotrophic lateral sclerosis. Brain Res.1070 (1), 206–214 (2006).
   PubMed Web of Science ®Google Scholar
• Tarnopolsky MA , BealMF. Potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders. Ann. Neurol.49 (5), 561–574 (2001).
   PubMed Web of Science ®Google Scholar
• Martin LJ . Olesoxime, a cholesterol-like neuroprotectant for the potential treatment of amyotrophic lateral sclerosis. IDrugs13 (8), 568–580 (2010).
   PubMed Web of Science ®Google Scholar
• Cudkowicz ME , Van Den BergLH, ShefnerJMet al. Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (empower): a randomised, double-blind, Phase 3 trial. Lancet Neurol.12 (11), 1059–1067 (2013).
   PubMed Web of Science ®Google Scholar
• Amante DJ , KimJ, CarreiroSTet al. Uridine ameliorates the pathological phenotype in transgenic G93A-ALS mice. Amyotroph. Lateral. Scler.11 (6), 520–530 (2010).
   PubMed Web of Science ®Google Scholar
• Park JH , HongYH, KimHJet al. Neurosci. Lett. 413 (3), 265–269 (2007).
   PubMed Web of Science ®Google Scholar
• Miquel E , CassinaA, Martinez-PalmaLet al. Modulation of astrocytic mitochondrial function by dichloroacetate improves survival and motor performance in inherited amyotrophic lateral sclerosis. PLoS ONE7 (4), e34776 (2012).
   PubMed Web of Science ®Google Scholar
• Kunst CB . Complex genetics of amyotrophic lateral sclerosis. Am. J. Hum. Genet.75 (6), 933–947 (2004).
   PubMed Web of Science ®Google Scholar
• Al-Saif A , Al-MohannaF, BohlegaS. A mutation in sigma-1 receptor causes juvenile amyotrophic lateral sclerosis. Ann. Neurol.70 (6), 913–919 (2011).
   PubMed Web of Science ®Google Scholar
• Niitsu T , IyoM, HashimotoK. Sigma-1 receptor agonists as therapeutic drugs for cognitive impairment in neuropsychiatric diseases. Curr. Pharm. Des.18 (7), 875–883 (2012).
   PubMed Web of Science ®Google Scholar
• Mancuso R , OlivanS, RandoA, CasasC, OstaR, NavarroX. Sigma-1r agonist improves motor function and motoneuron survival in ALS mice. Neurotherapeutics9 (4), 814–826 (2012).
   PubMed Web of Science ®Google Scholar
• Nutini M , SpalloniA, FlorenzanoFet al. Increased expression of the beta3 subunit of voltage-gated Na+ channels in the spinal cord of the SOD1G93A mouse. Mol. Cell. Neurosci.47 (2), 108–118 (2011).
   PubMed Web of Science ®Google Scholar
• Bellingham MC . Pre- and postsynaptic mechanisms underlying inhibition of hypoglossal motor neuron excitability by riluzole. J. Neurophysiol.110 (5), 1047–1061 (2013).
   PubMed Web of Science ®Google Scholar
• Edmonds HL Jr. , JiangYD, ZhangPY, ShankR. Topiramate as a neuroprotectant in a rat model of global ischemia-induced neurodegeneration. Life Sci.69 (19), 2265–2277 (2001).
   PubMed Web of Science ®Google Scholar
• Bermejo PE , AncionesB. A review of the use of zonisamide in Parkinson's disease. Ther. Adv. Neurol. Disord.2 (5), 313–317 (2009).
   PubMedGoogle Scholar
• Teng YD , WrathallJR. Local blockade of sodium channels by tetrodotoxin ameliorates tissue loss and long-term functional deficits resulting from experimental spinal cord injury. J. Neurosci.17 (11), 4359–4366 (1997).
   PubMed Web of Science ®Google Scholar
• Feng HL , LengY, MaCH, ZhangJ, RenM, ChuangDM. Combined lithium and valproate treatment delays disease onset, reduces neurological deficits and prolongs survival in an amyotrophic lateral sclerosis mouse model. Neuroscience155 (3), 567–572 (2008).
   PubMed Web of Science ®Google Scholar
• Ryberg H , AskmarkH, PerssonLI. A double-blind randomized clinical trial in amyotrophic lateral sclerosis using lamotrigine: effects on csf glutamate, aspartate, branched-chain amino acid levels and clinical parameters. Acta Neurol. Scand.108 (1), 1–8 (2003).
   PubMed Web of Science ®Google Scholar
• Conforti FL , SpataroR, SprovieroWet al. Ataxin-1 and ataxin-2 intermediate-length polyq expansions in amyotrophic lateral sclerosis. Neurology79 (24), 2315–2320 (2012).
   PubMed Web of Science ®Google Scholar
• Tanaka K , KannoT, YanagisawaYet al. Bromocriptine methylate suppresses glial inflammation and moderates disease progression in a mouse model of amyotrophic lateral sclerosis. Exp. Neurol.232 (1), 41–52 (2011).
   PubMed Web of Science ®Google Scholar
• Meyer T , SchwanA, DullingerJSet al. Early-onset ALS with long-term survival associated with spastin gene mutation. Neurology65 (1), 141–143 (2005).
   PubMed Web of Science ®Google Scholar
• Fanara P , BanerjeeJ, HueckRVet al. Stabilization of hyperdynamic microtubules is neuroprotective in amyotrophic lateral sclerosis. J. Biol. Chem.282 (32), 23465–23472 (2007).
   PubMed Web of Science ®Google Scholar
• Gonzalez-Perez P , CirulliET, DroryVEet al. Novel mutation in VCP gene causes atypical amyotrophic lateral sclerosis. Neurology79 (22), 2201–2208 (2012).
   PubMed Web of Science ®Google Scholar
• Rodriguez-Ortiz CJ , HoshinoH, ChengDet al. Neuronal-specific overexpression of a mutant valosin-containing protein associated with IBMPFD promotes aberrant ubiquitin and TDP-43 accumulation and cognitive dysfunction in transgenic mice. Am. J. Pathol.183 (2), 504–515 (2013).
   PubMed Web of Science ®Google Scholar
• Budini M , BaralleFE, BurattiE. Regulation of gene expression by TDP-43 and FUS/TLS in frontotemporal lobar degeneration. Curr. Alzheimer Res.8 (3), 237–245 (2011).
   PubMed Web of Science ®Google Scholar
• Lagier-Tourenne C , ClevelandDW. Rethinking ALS: The fus about tdp-43. Cell136 (6), 1001–1004 (2009).
   PubMed Web of Science ®Google Scholar
• Hotta K , NashimotoA, YasumuraEet al. Vesnarinone suppresses TNFalpha mRNA expression by inhibiting valosin-containing protein. Mol. Pharmacol.83 (5), 930–938 (2013).
   PubMed Web of Science ®Google Scholar
• Sasazawa Y , KanagakiS, TashiroEet al. Xanthohumol impairs autophagosome maturation through direct inhibition of valosin-containing protein. ACS Chem. Biol.7 (5), 892–900 (2012).
   PubMed Web of Science ®Google Scholar
• Suzumura A , SawadaM. Effects of vesnarinone on cytokine production and activation of murine microglia. Life Sci.64 (14), 1197–1203 (1999).
   PubMed Web of Science ®Google Scholar
• Yen TL , HsuCK, LuWJet al. Neuroprotective effects of xanthohumol, a prenylated flavonoid from hops (humulus lupulus), in ischemic stroke of rats. J. Agric. Food Chem.60 (8), 1937–1944 (2012).
   PubMed Web of Science ®Google Scholar
• Mitchell J , PaulP, ChenHJet al. Familial amyotrophic lateral sclerosis is associated with a mutation in d-amino acid oxidase. Proc. Natl Acad. Sci. USA107 (16), 7556–7561 (2010).
   PubMed Web of Science ®Google Scholar
• Sasabe J , MiyoshiY, SuzukiMet al. D-amino acid oxidase controls motoneuron degeneration through d-serine. Proc. Natl Acad. Sci. USA109 (2), 627–632 (2012).
   PubMed Web of Science ®Google Scholar
• Lin CH , ChenPK, ChangYCet al. Benzoate, a d-amino acid oxidase inhibitor, for the treatment of early-phase Alzheimer disease: a randomized, double-blind, placebo-controlled trial. Biol. Psychiatry75 (9), 678–685 (2013).
   PubMed Web of Science ®Google Scholar
• Adage T , TrillatAC, QuattropaniAet al. In vitro and in vivo pharmacological profile of AS057278, a selective d-amino acid oxidase inhibitor with potential anti-psychotic properties. Eur. Neuropsychopharmacol.18 (3), 200–214 (2008).
   PubMed Web of Science ®Google Scholar
• Smith SM , UslanerJM, HutsonPH. The therapeutic potential of d-amino acid oxidase (DAAO) inhibitors. Open Med. Chem. J.4, 3–9 (2010).
   PubMedGoogle Scholar
• Wu J , SongR, SongWet al. Chlorpromazine protects against apoptosis induced by exogenous stimuli in the developing rat brain. PLoS ONE6 (7), e21966 (2011).
   PubMed Web of Science ®Google Scholar
• Giordano G , ColeTB, FurlongCE, CostaLG. Paraoxonase 2 (PON2) in the mouse central nervous system: a neuroprotective role?Toxicol. Appl. Pharmacol.256 (3), 369–378 (2011).
   PubMed Web of Science ®Google Scholar
• Saeed M , SiddiqueN, HungWYet al. Paraoxonase cluster polymorphisms are associated with sporadic ALS. Neurology67 (5), 771–776 (2006).
   PubMed Web of Science ®Google Scholar
• Kalonia H , KumarP, KumarA, NehruB. Protective effect of montelukast against quinolinic acid/malonic acid induced neurotoxicity: possible behavioral, biochemical, mitochondrial and tumor necrosis factor-alpha level alterations in rats. Neuroscience171 (1), 284–299 (2010).
   PubMed Web of Science ®Google Scholar
• Bae J , LeeD, KimYK, GilM, LeeJY, LeeKJ. Berberine protects 6-hydroxydopamine-induced human dopaminergic neuronal cell death through the induction of heme oxygenase-1. Mol. Cells35 (2), 151–157 (2013).
   PubMed Web of Science ®Google Scholar